Measuring the burden of comorbidity for ischaemic heart disease and four common non-communicable diseases in Iran, 1990-2017: a modelling study based on global burden of diseases data.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
17 11 2022
Historique:
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: epublish

Résumé

This modelling study aimed to estimate the comorbidity burden for four common non-communicable diseases with ischaemic heart diseases (IHD) in Iran during a period of 28 years. Analysis of the burden of comorbidity with IHD based on data included prevalence rates and the disability weight (DW) average for calculating years lived with disability (YLDs) from the Iran population based on the Global Burden of Disease (GBD) study. Population-based available data in GBD 2017 study of Iran population. The source of data was the GBD 2017 Study. We evaluated IHD, major depressive disorder (MDD), diabetes mellitus (DM), ischaemic stroke (IS), and osteoarthritis (OA) age-standardised prevalence rates and their DW. A new formula that modified the GBD calculator was used to measure the comorbidity YLDs. In the new formula, some multipliers were considered, measuring the departure from independence. The contribution of total comorbidity for each combination of IHD with DM, MDD, IS and OA was 2.5%, 2.0%, 1.6% and 2.9%, respectively. The highest YLD rates were observed for IHD_MDD, 16.5 in 1990 and 17.0 in 2017. This was followed by IHD_DM, from 11.5 to 16.9 per 100 000. The YLD rates for IHD_OA changed slightly (6.5-6.7) per 100 000, whereas there was a gradual reduction in the trends of IHD-IS, from 4.0-4.5 per 100 000. Of the four comorbidities studied, the highest burden was due to the coexistence of MDD with IHD. Our results highlight the importance of addressing the burden of comorbidities when studying the burden of IHD or any other non-communicable disease.

Identifiants

pubmed: 36396302
pii: bmjopen-2021-054441
doi: 10.1136/bmjopen-2021-054441
pmc: PMC9677042
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e054441

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMC Nephrol. 2015 Dec 01;16:193
pubmed: 26620131
Int J Mol Sci. 2018 Mar 10;19(3):
pubmed: 29534462
World J Clin Cases. 2015 May 16;3(5):418-29
pubmed: 25984516
J Urol. 2018 Feb;199(2):543-550
pubmed: 28789948
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Int J Rheum Dis. 2016 Nov;19(11):1056-1062
pubmed: 26620687
Lancet. 2010 Jul 10;376(9735):112-23
pubmed: 20561675
Int J Prev Med. 2010 Spring;1(2):81-91
pubmed: 21566767
PLoS One. 2014 Aug 29;9(8):e106248
pubmed: 25170612
J Tehran Heart Cent. 2018 Oct;13(4):195-197
pubmed: 30972121
Iran J Psychiatry. 2018 Jan;13(1):55-64
pubmed: 29892318
J Headache Pain. 2021 Jul 14;22(1):71
pubmed: 34261435
Diabetes Res Clin Pract. 2018 Aug;142:345-352
pubmed: 29802955
Eur Heart J. 2018 Feb 14;39(7):578-585
pubmed: 28430901
Arthritis Rheumatol. 2019 Nov;71(11):1835-1843
pubmed: 31389178
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
BMC Med Res Methodol. 2013 Jul 16;13:92
pubmed: 23855337
Lancet. 2007 Sep 8;370(9590):851-8
pubmed: 17826170
BMC Public Health. 2008 Jun 27;8:221
pubmed: 18582390
Acta Cardiol. 2006 Feb;61(1):13-20
pubmed: 16485728
Sci Rep. 2016 Dec 22;6:39672
pubmed: 28004796
Int J Chron Obstruct Pulmon Dis. 2016 Sep 14;11:2229-2236
pubmed: 27695310
Lung. 2018 Apr;196(2):239-248
pubmed: 29230534
J Vasc Surg. 2001 Feb;33(2):345-52
pubmed: 11174788
Curr Opin Cardiol. 2007 Jul;22(4):286-91
pubmed: 17556879
Iran J Neurol. 2017 Oct 7;16(4):201-209
pubmed: 29736226
Ann Rheum Dis. 2003 May;62(5):495
pubmed: 12695176
Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):455-6
pubmed: 26152681
Ann Behav Med. 2014 Oct;48(2):142-4
pubmed: 24722962

Auteurs

Marjan Mansourian (M)

Barcelona Tech (UPC), Universitat Politecnica de Catalunya, Barcelona, Spain.

Khojasteh Ghasemi (K)

Cardiovascular Research Institute, Interventional Cardiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).

AliAkbar Haghdoost (A)

Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran (the Islamic Republic of).

Jacek A Kopec (JA)

School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.

Nizal Sarrafzadegan (N)

School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada nsarrafzadegan@gmail.com.
Cardiovascular Research Institute, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).

Sheikh Mohammed Shariful Islam (SMS)

Institute for Physical Activity and Nutrition, Deakin University, Burwood, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH